Unlock free Digest editor
Roula Khalaf, editor of FT, chooses her favorite story in this weekly newsletter.
The Astrazeneca is pulled out of its plans to build a £ 450 million vaccine production plant after months of breaking through British officials about the state investment for the Merseyside project, at a great hit of the Prime Minister Sir Keira Starmer.
This month, officials presented a revised offer of financial support for that place in Speke, which was significantly more than £ 40 million offered last year, said people who know about arrangements.
The Starmer Labor Government sought last summer to reduce the amount of state support, which was provided with a project with around £ 90m to £ 40m, according to the people who sent in that issue.
“After long discussions with the Government, we no longer implement our planned investment in Speke,” Astrazenec said in a statement on Friday. “Several factors have influenced this decision, including the time and reduction of the final offer relative to the proposal of the previous government.”
The existing location of the specta will continue to produce and supply the flu vaccine, the company said.
The previous offer of former Conservative Chancellor Jeremy Hunt included up to £ 70m in scholarships for the development of the existing Astrazeneca Speke vaccine vaccine, as well as £ 20m in the research and the development of the UK support, the Health Security Agency, people said.
The treasury did not immediately respond to the commentary request.
People close to the pharmaceutical company said they were watching other possible production sites.
Maderka drugs, the largest British company in market capitalization, became “deeply frustrated” with the Government of the UK, said another person, with a speck with just one point of tension in a broader conflict in the industry because of the prices of medicines and the future of investment in life science.
In November, Astrazeneca announced that she plans to invest $ 3.5 billion in research and development and production in the United States, the world’s largest pharmaceutical market, which generates 44 percent of the company sales.
The Pascal Sorit CEO of Astrazenec said at the time that the investment reflected “the attraction of the business environment together with the quality of talent and innovation abilities.”
The company also plans to produce a production facility of $ 1.5 billion in Singapore, and last week in Canada has pledged an investment of $ 560 million.
There is no suggestion that his decision on the specta facility would affect any of the other investments of the Astrazenec in the UK, said people who know about work.
In March, the then conservative government in the UK said Astrazeneca would invest £ 450 million in research, development and production of new vaccines in Speke.
The Financial Times reported at a time when the company wanted to secure up to £ 100 million of state support.
